Kelso Pharma appointment at Italian subsidiary

UK-based specialty drugmaker Kelso Pharma has appointed experienced pharma executive, Giovanni Mauri, as general manager at Velit Biopharma, the Italian-based pharma business that was acquired by Kelso in November 2023.

With a wealth of experience across a variety of key markets in the life sciences sector, Mr Mauri specializes in strategic business development and licensing operations and brings with him significant experience in legal and compliance. Mr Mauri’s previous roles have included as business development manager at Bausch + Lomb (NYSE/TSX: BLCO), the largest global provider of eye care products, and chief business development officer at NTC Pharma, an international R&D-driven pharmaceuticals company. Dr Nicola Travierso, founder of Velit Biopharma, will act as a senior advisor to Mr Mauri.

Velit Biopharma specializes in developing and registering “hard to make” medicines and medical devices which it then makes available to patients through partnerships with pharmaceutical companies and distributors across Europe, Asia, Middle East and Africa. It has more than 100 partnerships in 48 regions/countries covering 167 products.